Shire (SHP) Shares Down 2.9%
Shire PLC (LON:SHP)’s share price was down 2.9% on Monday . The stock traded as low as GBX 3,083.50 ($42.60) and last traded at GBX 3,110.50 ($42.97). Approximately 1,890,000 shares traded hands during trading, a decline of 39% from the average daily volume of 3,110,000 shares. The stock had previously closed at GBX 3,202 ($44.24).
Several equities analysts have recently weighed in on SHP shares. Shore Capital reiterated a “buy” rating on shares of Shire in a report on Monday, November 13th. Berenberg Bank upped their price objective on shares of Shire from GBX 5,900 ($81.51) to GBX 6,000 ($82.90) and gave the company a “buy” rating in a report on Monday, November 6th. Kepler Capital Markets reiterated a “buy” rating and set a GBX 4,600 ($63.55) price objective on shares of Shire in a report on Wednesday, November 1st. Deutsche Bank dropped their price objective on shares of Shire from GBX 5,700 ($78.75) to GBX 5,500 ($75.99) and set a “buy” rating on the stock in a report on Wednesday, November 1st. Finally, Citigroup reiterated a “buy” rating and set a GBX 5,500 ($75.99) price objective on shares of Shire in a report on Monday, October 30th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Shire has a consensus rating of “Buy” and an average price target of GBX 5,173.53 ($71.48).
The firm has a market capitalization of $28,300.00 and a PE ratio of 600.48.
In related news, insider Dominic Blakemore bought 165 shares of Shire stock in a transaction dated Tuesday, December 19th. The stock was purchased at an average cost of GBX 3,790 ($52.36) per share, with a total value of £6,253.50 ($8,639.82).
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.